| 131.06 -0.9 (-0.68%) | 07-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 164.62 | 1-year : | 176.25 |
| Resists | First : | 140.94 | Second : | 150.89 |
| Pivot price | 141.63  |
|||
| Supports | First : | 124.84 | Second : | 103.87 |
| MAs | MA(5) : | 135.54 |
MA(20) : | 141.03 |
| MA(100) : | 125.16  |
MA(250) : | 136.59 |
|
| MACD | MACD : | 0.9 |
Signal : | 3.1 |
| %K %D | K(14,3) : | 20.7 |
D(3) : | 32.4 |
| RSI | RSI(14): 41.1 |
|||
| 52-week | High : | 175.77 | Low : | 100.98 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RGEN ] has closed above bottom band by 2.0%. Bollinger Bands are 0.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 133.52 - 134.6 | 134.6 - 135.33 |
| Low: | 127.78 - 128.97 | 128.97 - 129.78 |
| Close: | 129.49 - 131.35 | 131.35 - 132.59 |
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Mon, 27 Jul 2026
Repligen (RGEN) Q2 Earnings: What To Expect - Yahoo! Finance Canada
Mon, 27 Jul 2026
ETFs Investing in Repligen Corporation Stocks - TradingView
Fri, 24 Jul 2026
Repligen Corporation Revenue Breakdown – NASDAQ:RGEN - TradingView
Fri, 24 Jul 2026
Is Repligen Corp (RGEN) a Bargain After 4.1% Drop? GF Value Says Undervalued - GuruFocus
Thu, 23 Jul 2026
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout - Yahoo Finance
Wed, 22 Jul 2026
Repligen beefs up cell therapy business with $1.5 billion deal for BioLife - Reuters
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 56 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 5.2 (%) |
| Held by Institutions | 120.1 (%) |
| Shares Short | 5,810 (K) |
| Shares Short P.Month | 5,730 (K) |
| EPS | 0.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 37.33 |
| Profit Margin | 6.7 % |
| Operating Margin | 8.8 % |
| Return on Assets (ttm) | 1.1 % |
| Return on Equity (ttm) | 2.5 % |
| Qtrly Rev. Growth | 14.8 % |
| Gross Profit (p.s.) | 7.19 |
| Sales Per Share | 13.53 |
| EBITDA (p.s.) | 2.37 |
| Qtrly Earnings Growth | 47.9 % |
| Operating Cash Flow | 131 (M) |
| Levered Free Cash Flow | 69 (M) |
| PE Ratio | 144.02 |
| PEG Ratio | 2.1 |
| Price to Book value | 3.51 |
| Price to Sales | 9.68 |
| Price to Cash Flow | 56.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|